When do you evaluate patients with Parkinson's disease and cognitive decline for concurrent Alzheimer's disease? 

Parkinson’s disease (PD) often includes Alzheimer’s disease (AD) “co-pathology” in up to 80% of cases. This challenges the notion that PD is a synucleinopathy; it affects many proteins beyond α-synuclein. Thus, cognitive decline in PD may be associated with AD pathology, and one of the strongest pre...

In general, I always ask myself and the patient, "What will we do with the results of a test?" Cognitive decline is part of Parkinson's disease (PD). Symptomatic treatment with rivastigmine (or other acetylcholinesterase inhibitors) and memantine can be helpful without the need for further testing f...